

# Lars Bastholt

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/228943/lars-bastholt-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122  
papers

15,203  
citations

40  
h-index

123  
g-index

127  
ext. papers

18,946  
ext. citations

7.3  
avg, IF

5.81  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 122 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 23-34  | 59.2 | 5047      |
| 121 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1535-1546  | 59.2 | 1260      |
| 120 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , <b>2014</b> , 384, 319-28  | 40   | 933       |
| 119 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1845-1855   | 59.2 | 870       |
| 118 | Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , <b>2020</b> , 577, 561-565  | 56.4 | 542       |
| 117 | Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. <i>Lancet, The</i> , <b>2003</b> , 362, 933-40  | 40   | 506       |
| 116 | A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. <i>Radiotherapy and Oncology</i> , <b>1998</b> , 46, 135-46 | 5.3  | 451       |
| 115 | A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , <b>2011</b> , 9, 204   | 8.5  | 412       |
| 114 | Motesanib diphosphate in progressive differentiated thyroid cancer. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 31-42  | 59.2 | 397       |
| 113 | Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 611-622  | 21.7 | 306       |
| 112 | Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3794-801  | 2.2  | 293       |
| 111 | Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1989-2007   | 7.5  | 292       |
| 110 | Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 897-905   | 21.7 | 273       |
| 109 | Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. <i>European Journal of Cancer</i> , <b>2016</b> , 63, 201-17  | 7.5  | 265       |
| 108 | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 555-67   | 12.9 | 238       |
| 107 | Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. <i>Journal of Oral and Maxillofacial Surgery</i> , <b>2000</b> , 58, 1088-93; discussion 1093-5   | 1.8  | 201       |
| 106 | Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2396-403   | 7.5  | 170       |

|     |   |      |     |
|-----|---|------|-----|
| 105 | Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. <i>European Journal of Cancer</i> , <b>2019</b> , 118, 10-34  | 7.5  | 152 |
| 104 | Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. <i>Radiotherapy and Oncology</i> , <b>1997</b> , 43, 47-51   | 5.3  | 109 |
| 103 | Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5117-25   | 2.2  | 100 |
| 102 | Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. <i>Acta Oncologica</i> , <b>1994</b> , 33, 487-91  | 3.2  | 93  |
| 101 | Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 144-52  | 21.7 | 85  |
| 100 | European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. <i>European Journal of Cancer</i> , <b>2020</b> , 126, 159-177  | 7.5  | 81  |
| 99  | The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 3636-41          | 5.6  | 80  |
| 98  | European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , <b>2020</b> , 128, 83-102  | 7.5  | 76  |
| 97  | Salvage laryngectomy and pharyngocutaneous fistulae after primary radiotherapy for head and neck cancer: a national survey from DAHANCA. <i>Head and Neck</i> , <b>2003</b> , 25, 711-6   | 4.2  | 73  |
| 96  | Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3831-7         | 2.2  | 70  |
| 95  | Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 869-77   | 9.7  | 68  |
| 94  | Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 3424-8 | 5.6  | 68  |
| 93  | European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. <i>European Journal of Cancer</i> , <b>2020</b> , 126, 141-158  | 7.5  | 63  |
| 92  | European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , <b>2020</b> , 128, 60-82  | 7.5  | 60  |
| 91  | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 643-654                | 21.7 | 58  |
| 90  | The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. <i>European Journal of Cancer</i> , <b>2017</b> , 74, 89-95  | 7.5  | 57  |
| 89  | Cancer of the larynx--treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients. <i>Acta Oncologica</i> , <b>2002</b> , 41, 69-76  | 3.2  | 57  |
| 88  | Interleukin-6 and melanoma. <i>Melanoma Research</i> , <b>2012</b> , 22, 327-33   | 3.3  | 55  |

|    |  |     |    |
|----|--|-----|----|
| 87 | Hypopharyngeal cancer: results of treatment based on radiation therapy and salvage surgery. <i>Laryngoscope</i> , <b>2002</b> , 112, 834-8   | 3.6 | 54 |
| 86 | A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1991</b> , 28, 465-9       | 3.5 | 48 |
| 85 | Papillary thyroid microcarcinoma in Denmark 1996-2008: a national study of epidemiology and clinical significance. <i>Thyroid</i> , <b>2013</b> , 23, 1159-64  | 6.2 | 45 |
| 84 | Lymph node metastases from laryngeal and pharyngeal carcinomas--calculation of burden of metastasis and its impact on prognosis. <i>Acta Oncologica</i> , <b>1998</b> , 37, 489-93   | 3.2 | 45 |
| 83 | Papillary thyroid carcinoma in Denmark, 1996-2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. <i>Thyroid</i> , <b>2015</b> , 25, 78-84   | 6.2 | 44 |
| 82 | Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. <i>Melanoma Research</i> , <b>2012</b> , 22, 287-93  | 3.3 | 40 |
| 81 | Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 3981-4                  | 5.6 | 40 |
| 80 | Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4-4                                      | 2.2 | 39 |
| 79 | Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 3719-25              | 5.6 | 36 |
| 78 | Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. <i>Laryngoscope</i> , <b>1998</b> , 108, 243-9  | 3.6 | 34 |
| 77 | Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFR (HuMax-EGFR) in patients with advanced squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 85, 24-8 | 5.3 | 34 |
| 76 | Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1991</b> , 28, 63-8  | 3.5 | 33 |
| 75 | Papillary thyroid carcinoma in Denmark 1996-2008: an investigation of changes in incidence. <i>Cancer Epidemiology</i> , <b>2013</b> , 37, e1-6  | 2.8 | 32 |
| 74 | Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 2653-60                  | 5.6 | 32 |
| 73 | Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. <i>Onc Immunology</i> , <b>2018</b> , 7, e1424674  | 7.2 | 29 |
| 72 | Osseointegrated implants for prosthetic rehabilitation after treatment of cancer of the oral cavity. <i>Acta Oncologica</i> , <b>1997</b> , 36, 37-40  | 3.2 | 28 |
| 71 | Duration of symptoms: impact on outcome of radiotherapy in glottic cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 61, 789-94  | 4   | 27 |
| 70 | Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging. <i>Thyroid</i> , <b>2002</b> , 12, 313-7  | 6.2 | 27 |

|    |  |     |    |
|----|--|-----|----|
| 69 | The real-world impact of modern treatments on the survival of patients with metastatic melanoma. <i>European Journal of Cancer</i> , <b>2019</b> , 108, 25-32  | 7.5 | 26 |
| 68 | The Danish national guidelines for treatment of oral squamous cell carcinoma. <i>Acta Oncologica</i> , <b>2006</b> , 45, 294-9   | 3.2 | 24 |
| 67 | Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. <i>Clinical Pharmacology and Therapeutics</i> , <b>1989</b> , 45, 627-34  | 6.1 | 24 |
| 66 | Prognostic stratification of ulcerated melanoma: not only the extent matters. <i>American Journal of Clinical Pathology</i> , <b>2014</b> , 142, 845-56  | 1.9 | 21 |
| 65 | Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. <i>Melanoma Research</i> , <b>2016</b> , 26, 367-76   | 6.3 | 21 |
| 64 | Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma <b>2020</b> , 8,   |     | 19 |
| 63 | Completeness and validity in a national clinical thyroid cancer database: DATHYRCA. <i>Cancer Epidemiology</i> , <b>2014</b> , 38, 633-7   | 2.8 | 19 |
| 62 | Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. <i>Oncolmunology</i> , <b>2013</b> , 2, e23288  | 7.2 | 19 |
| 61 | Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease?. <i>Acta Oncologica</i> , <b>2008</b> , 47, 451-7  | 3.2 | 19 |
| 60 | A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 77, 143-7  | 5.3 | 19 |
| 59 | Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. <i>Breast Cancer Research and Treatment</i> , <b>2000</b> , 61, 103-10 | 4.4 | 19 |
| 58 | Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2773-2781  | 2.2 | 18 |
| 57 | Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , <b>2019</b> , 11,   | 6.6 | 17 |
| 56 | A phase II study of thalidomide in patients with brain metastases from malignant melanoma. <i>Acta Oncologica</i> , <b>2008</b> , 47, 1526-30  | 3.2 | 17 |
| 55 | The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1994</b> , 35, 45-52  | 3.5 | 17 |
| 54 | CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 299-303   | 4.3 | 16 |
| 53 | Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>European Journal of Cancer</i> , <b>2019</b> , 119, 122-131  | 7.5 | 15 |
| 52 | A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer. <i>European Thyroid Journal</i> , <b>2013</b> , 2, 195-202   | 4.2 | 14 |

|    |   |      |    |
|----|---|------|----|
| 51 | Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4-4   | 2.2  | 14 |
| 50 | High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study. <i>Gynecologic Oncology</i> , <b>1992</b> , 44, 79-82   | 4.9  | 11 |
| 49 | Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6060-6060 | 2.2  | 11 |
| 48 | Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form. <i>Health and Quality of Life Outcomes</i> , <b>2018</b> , 16, 77   | 3    | 10 |
| 47 | Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , <b>2016</b> , 5, 187-194  | 4.2  | 10 |
| 46 | The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma. <i>Journal of Immunotherapy</i> , <b>2007</b> , 30, 773-9  | 5    | 10 |
| 45 | The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. <i>Melanoma Research</i> , <b>2018</b> , 28, 333-340  | 3.3  | 10 |
| 44 | Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 349-55   | 7.4  | 9  |
| 43 | MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin. <i>Melanoma Research</i> , <b>2015</b> , 25, 113-8  | 3.3  | 9  |
| 42 | Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. <i>Acta Oncologica</i> , <b>2013</b> , 52, 1086-93            | 3.2  | 9  |
| 41 | Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. <i>Melanoma Research</i> , <b>2013</b> , 23, 21-6   | 3.3  | 9  |
| 40 | Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients and Clinicians Experiences. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e14896  | 7.6  | 9  |
| 39 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 655-664                      | 21.7 | 9  |
| 38 | Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. <i>Journal of Patient-Reported Outcomes</i> , <b>2019</b> , 3, 19   | 2.6  | 8  |
| 37 | High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. <i>European Journal of Cancer</i> , <b>2019</b> , 115, 61-67   | 7.5  | 8  |
| 36 | Benefit of adjuvant interferon alfa-2b (IFN- $\beta$ ) therapy in melanoma patients with high serum MMP-8 levels. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 173-80  | 7.4  | 8  |
| 35 | Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , <b>2020</b> , 133, 94-103 | 7.5  | 8  |
| 34 | Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites. <i>Hypertension</i> , <b>2018</b> , 71, 473-480  | 8.5  | 8  |



|    |  |      |   |
|----|--|------|---|
| 33 | The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients. <i>EJNMMI Research</i> , <b>2016</b> , 6, 73  | 3.6  | 8 |
| 32 | Large discrepancy in the results of sensitive measurements of thyroglobulin antibodies in the follow-up on thyroid cancer: a diagnostic dilemma. <i>European Thyroid Journal</i> , <b>2012</b> , 1, 193-7  | 4.2  | 8 |
| 31 | Weekly oral idarubicin in advanced prostatic cancer. A phase II study. <i>Acta Oncologica</i> , <b>1992</b> , 31, 337-40   | 3.2  | 8 |
| 30 | Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries. <i>American Journal of Therapeutics</i> , <b>2015</b> , 22, 37-43   | 1    | 7 |
| 29 | Side effects and toxicities of targeted therapies in stage IV melanoma. <i>American Journal of Therapeutics</i> , <b>2015</b> , 22, 44-53  | 1    | 7 |
| 28 | A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1991</b> , 28, 205-10  | 3.5  | 7 |
| 27 | Multiple endocrine neoplasia type 2: A review. <i>Seminars in Cancer Biology</i> , <b>2021</b> ,   | 12.7 | 7 |
| 26 | The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , <b>2021</b> , 73, 101943   | 2.8  | 7 |
| 25 | Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid Tissue. <i>European Thyroid Journal</i> , <b>2017</b> , 6, 276-280   | 4.2  | 6 |
| 24 | The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3173-3174  | 7.5  | 6 |
| 23 | Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanoma. <i>Acta Oncologica</i> , <b>2017</b> , 56, 109-110   | 3.2  | 6 |
| 22 | The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1994</b> , 34, 439-43                          | 3.5  | 6 |
| 21 | Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6061-6061                | 2.2  | 6 |
| 20 | Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration. <i>American Journal of Dermatopathology</i> , <b>2017</b> , 39, 672-678   | 0.9  | 5 |
| 19 | Trends in melanoma in the elderly in Denmark, 1980-2012. <i>Acta Oncologica</i> , <b>2016</b> , 55 Suppl 1, 52-8   | 3.2  | 5 |
| 18 | Consumption of the epidermis: a suggested precursor of ulceration associated with increased proliferation of melanoma cells. <i>American Journal of Dermatopathology</i> , <b>2015</b> , 37, 841-5   | 0.9  | 5 |
| 17 | The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. <i>Journal of Patient-Reported Outcomes</i> , <b>2020</b> , 4, 88  | 2.6  | 5 |
| 16 | Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 156-168 | 7.5  | 5 |

|    |   |     |   |
|----|---|-----|---|
| 15 | Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for Prognostication. <i>Anticancer Research</i> , <b>2016</b> , 36, 749-56  | 2.3 | 5 |
| 14 | Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2100714   | 2.2 | 4 |
| 13 | Comment on Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines <i>European Journal of Cancer</i> , <b>2020</b> , 131, 100-103  | 7.5 | 3 |
| 12 | A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6021-6021 | 2.2 | 3 |
| 11 | Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. <i>Cancer Immunology, Immunotherapy</i> , <b>2015</b> , 64, 769-76  | 7.4 | 2 |
| 10 | Stabilization of circulating thyroglobulin mRNA transcripts in patients treated for differentiated thyroid carcinoma. <i>Annals of Clinical Biochemistry</i> , <b>2017</b> , 54, 558-566  | 2.2 | 2 |
| 9  | Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. <i>European Journal of Cancer</i> , <b>2019</b> , 121, 74-84  | 7.5 | 1 |
| 8  | A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. <i>Acta Oncologica</i> , <b>2007</b> , 46, 374-7   | 3.2 | 1 |
| 7  | Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. <i>Cancers</i> , <b>2021</b> , 13,  | 6.6 | 1 |
| 6  | Response to: Comment on Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines <i>European Journal of Cancer</i> , <b>2020</b> , 140, 154-157   | 7.5 | 1 |
| 5  | Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial.. <i>Journal of Patient-Reported Outcomes</i> , <b>2022</b> , 6, 8   | 2.6 | 0 |
| 4  | The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2022</b> , 1   | 8.8 | 0 |
| 3  | Genetic predisposition to long telomeres is associated with increased mortality after melanoma: A study of 2101 melanoma patients from hospital clinics and the general population. <i>Pigment Cell and Melanoma Research</i> , <b>2021</b> , 34, 946-954   | 4.5 | 0 |
| 2  | Immunotherapy in Patients with mCRC <b>2021</b> , 183-186   |     |   |
| 1  | Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8545-8545  | 2.2 |   |